{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Oncology"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "28768903", "DateRevised": {"Year": "2019", "Month": "11", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "08", "Day": "03"}], "Language": ["eng"], "ELocationID": ["e93313", "10.1172/jci.insight.93313", "93313"], "Journal": {"ISSN": "2379-3708", "JournalIssue": {"Volume": "2", "Issue": "15", "PubDate": {"Year": "2017", "Month": "Aug", "Day": "03"}}, "Title": "JCI insight", "ISOAbbreviation": "JCI Insight"}, "ArticleTitle": "microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer.", "Abstract": {"AbstractText": ["The tumor suppressor PTEN is frequently inactivated in breast and other cancers; yet, germ-line mutations in this gene induce nonmalignant hamartomas, indicating dependency on additional cooperating events. Here we show that most tumors derived from conditional deletion of mouse pten in mammary epithelium are highly differentiated and lack transplantable tumor-initiating cells (TICs) capable of seeding new tumors following orthotopic injection of FACS-sorted or tumorsphere cells. A rare group of poorly differentiated tumors did harbor transplantable TICs. These transplantable tumors exhibited distinct molecular classification, signaling pathways, chromosomal aberrations, and mutational landscape, as well as reduced expression of microRNA-143/145 (miR-143/145). Stable knockdown of miR-143/145 conferred tumorigenic potential upon poorly transplantable pten-deficient tumor cells through a mechanism involving induction of RAS signaling, leading to increased sensitivity to MEK inhibition. In humans, miR-145 deficiency significantly correlated with elevated RAS-pathway activity in basal-like breast cancer, and patients with combined PTEN/miR-145 loss or PTEN-loss/high RAS-pathway activity exhibited poor clinical outcome. These results underscore a selective pressure for combined PTEN loss together with RAS-pathway activation, either through miR-145 loss or other mechanisms, in basal-like breast cancer, and a need to identify and prioritize these tumors for aggressive therapy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, and."}], "LastName": "Wang", "ForeName": "Sharon", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}], "LastName": "Liu", "ForeName": "Jeff C", "Initials": "JC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}], "LastName": "Ju", "ForeName": "YoungJun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada."}], "LastName": "Pellecchia", "ForeName": "Giovanna", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada."}], "LastName": "Voisin", "ForeName": "Veronique", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}], "LastName": "Wang", "ForeName": "Dong-Yu", "Initials": "DY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}], "LastName": "Leha L", "ForeName": "Rajwinder", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, and State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Department of Molecular Genetics, and."}], "LastName": "Bader", "ForeName": "Gary D", "Initials": "GD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Advanced Diagnostics, Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, and."}, {"Identifier": [], "Affiliation": "Department of Medicine, University of Toronto, Toronto, Ontario, Canada."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "GrantList": [{"GrantID": "P41 GM103504", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "JCI Insight", "NlmUniqueID": "101676073", "ISSNLinking": "2379-3708"}, "CoiStatement": "<b>Conflict of interest:</b> The authors have declared that no conflict of interest exists."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u2013752. doi: 10.1038/35021093.", "ArticleIdList": ["10.1038/35021093", "10963602"]}, {"Citation": "Herschkowitz JI, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76. doi: 10.1186/gb-2007-8-5-r76.", "ArticleIdList": ["10.1186/gb-2007-8-5-r76", "PMC1929138", "17493263"]}, {"Citation": "Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635.", "ArticleIdList": ["10.1186/bcr2635", "PMC3096954", "20813035"]}, {"Citation": "Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;135(1):301\u2013306. doi: 10.1007/s10549-012-2143-0.", "ArticleIdList": ["10.1007/s10549-012-2143-0", "PMC3413822", "22752290"]}, {"Citation": "Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u2013352.", "ArticleIdList": ["PMC3440846", "22522925"]}, {"Citation": "Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354. doi: 10.1038/nature17676.", "ArticleIdList": ["10.1038/nature17676", "PMC4910866", "27135926"]}, {"Citation": "Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370. doi: 10.1038/nature11412.", "ArticleIdList": ["10.1038/nature11412", "PMC3465532", "23000897"]}, {"Citation": "Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403\u2013414. doi: 10.1016/j.cell.2008.04.013.", "ArticleIdList": ["10.1016/j.cell.2008.04.013", "18455982"]}, {"Citation": "Zacksenhaus E, et al. Transcription factors in breast cancer-lessons from recent genomic analyses and therapeutic implications. Adv Protein Chem Struct Biol. 2017;107:223\u2013273. doi: 10.1016/bs.apcsb.2016.10.003.", "ArticleIdList": ["10.1016/bs.apcsb.2016.10.003", "28215225"]}, {"Citation": "Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11(10):687\u2013694. doi: 10.1097/GIM.0b013e3181ac9aea.", "ArticleIdList": ["10.1097/GIM.0b013e3181ac9aea", "19668082"]}, {"Citation": "Ahmad I, et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A. 2011;108(39):16392\u201316397. doi: 10.1073/pnas.1101263108.", "ArticleIdList": ["10.1073/pnas.1101263108", "PMC3182686", "21930937"]}, {"Citation": "Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725\u2013730. doi: 10.1038/nature03918.", "ArticleIdList": ["10.1038/nature03918", "PMC1939938", "16079851"]}, {"Citation": "Liu JC, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 2014;6(12):1542\u20131560. doi: 10.15252/emmm.201404402.", "ArticleIdList": ["10.15252/emmm.201404402", "PMC4287974", "25330770"]}, {"Citation": "Naguib A, et al. PTEN functions by recruitment to cytoplasmic vesicles. Mol Cell. 2015;58(2):255\u2013268. doi: 10.1016/j.molcel.2015.03.011.", "ArticleIdList": ["10.1016/j.molcel.2015.03.011", "PMC4423730", "25866245"]}, {"Citation": "Song MS, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011;144(2):187\u2013199. doi: 10.1016/j.cell.2010.12.020.", "ArticleIdList": ["10.1016/j.cell.2010.12.020", "PMC3249980", "21241890"]}, {"Citation": "Shen WH, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157\u2013170. doi: 10.1016/j.cell.2006.11.042.", "ArticleIdList": ["10.1016/j.cell.2006.11.042", "17218262"]}, {"Citation": "Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Hopkins BD, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science. 2013;341(6144):399\u2013402. doi: 10.1126/science.1234907.", "ArticleIdList": ["10.1126/science.1234907", "PMC3935617", "23744781"]}, {"Citation": "Putz U, et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal. 2012;5(243):ra70.", "ArticleIdList": ["23012657"]}, {"Citation": "Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861\u2013874. doi: 10.1038/nrg3074.", "ArticleIdList": ["10.1038/nrg3074", "22094949"]}, {"Citation": "Xin M, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23(18):2166\u20132178. doi: 10.1101/gad.1842409.", "ArticleIdList": ["10.1101/gad.1842409", "PMC2751981", "19720868"]}, {"Citation": "Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18(10):1913\u20131926. doi: 10.1111/jcmm.12358.", "ArticleIdList": ["10.1111/jcmm.12358", "PMC4244007", "25124875"]}, {"Citation": "Iorio MV, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065\u20137070. doi: 10.1158/0008-5472.CAN-05-1783.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-1783", "16103053"]}, {"Citation": "Min W, et al. The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res. 2014;20:97\u2013104. doi: 10.12659/MSMBR.891246.", "ArticleIdList": ["10.12659/MSMBR.891246", "PMC4117676", "25047098"]}, {"Citation": "Suzuki A, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8(21):1169\u20131178. doi: 10.1016/S0960-9822(07)00488-5.", "ArticleIdList": ["10.1016/S0960-9822(07)00488-5", "9799734"]}, {"Citation": "Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development. 2002;129(6):1377\u20131386.", "ArticleIdList": ["11880347"]}, {"Citation": "Jiang Z, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest. 2010;120(9):3296\u20133309. doi: 10.1172/JCI41490.", "ArticleIdList": ["10.1172/JCI41490", "PMC2929714", "20679727"]}, {"Citation": "Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275\u2013291. doi: 10.1016/j.stem.2014.02.006.", "ArticleIdList": ["10.1016/j.stem.2014.02.006", "24607403"]}, {"Citation": "Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res. 2007;67(18):8671\u20138681. doi: 10.1158/0008-5472.CAN-07-1486.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-1486", "17875707"]}, {"Citation": "Jones RA, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016;126(10):3739\u20133757. doi: 10.1172/JCI81568.", "ArticleIdList": ["10.1172/JCI81568", "PMC5096803", "27571409"]}, {"Citation": "Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983\u20133988. doi: 10.1073/pnas.0530291100.", "ArticleIdList": ["10.1073/pnas.0530291100", "PMC153034", "12629218"]}, {"Citation": "Sflomos G, et al. A preclinical model for ER\u03b1-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407\u2013422. doi: 10.1016/j.ccell.2016.02.002.", "ArticleIdList": ["10.1016/j.ccell.2016.02.002", "26947176"]}, {"Citation": "Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984. doi: 10.1371/journal.pone.0013984.", "ArticleIdList": ["10.1371/journal.pone.0013984", "PMC2981572", "21085593"]}, {"Citation": "Forbes SA, et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805\u2013D811.", "ArticleIdList": ["PMC4383913", "25355519"]}, {"Citation": "Li Z, et al. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell. 2014;54(5):805\u2013819. doi: 10.1016/j.molcel.2014.03.046.", "ArticleIdList": ["10.1016/j.molcel.2014.03.046", "PMC4172312", "24793696"]}, {"Citation": "Pei XH, et al. Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis. Cancer Res. 2011;71(8):2969\u20132977. doi: 10.1158/0008-5472.CAN-10-4300.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-4300", "PMC3088989", "21487039"]}, {"Citation": "Dvinge H, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378\u2013382. doi: 10.1038/nature12108.", "ArticleIdList": ["10.1038/nature12108", "23644459"]}, {"Citation": "Iorio MV, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699\u20138707. doi: 10.1158/0008-5472.CAN-07-1936.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-1936", "17875710"]}, {"Citation": "Liu X, et al. Uncovering growth-suppressive microRNAs in lung cancer. Clin Cancer Res. 2009;15(4):1177\u20131183. doi: 10.1158/1078-0432.CCR-08-1355.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-1355", "PMC3749890", "19228723"]}, {"Citation": "Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705\u2013710.", "ArticleIdList": ["PMC2769203", "19578358"]}, {"Citation": "Gregory PA, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593\u2013601. doi: 10.1038/ncb1722.", "ArticleIdList": ["10.1038/ncb1722", "18376396"]}, {"Citation": "Greene SB, Herschkowitz JI, Rosen JM. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 2010;7(3):300\u2013304. doi: 10.4161/rna.7.3.11837.", "ArticleIdList": ["10.4161/rna.7.3.11837", "PMC3008649", "20436283"]}, {"Citation": "Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104(18):7564\u20137569. doi: 10.1073/pnas.0702507104.", "ArticleIdList": ["10.1073/pnas.0702507104", "PMC1855070", "17452630"]}, {"Citation": "Venner CP, et al. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013;98(3):409\u2013413. doi: 10.3324/haematol.2012.066068.", "ArticleIdList": ["10.3324/haematol.2012.066068", "PMC3659949", "22929976"]}, {"Citation": "Su J, et al. MiR-143 and miR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One. 2014;9(12):e114420. doi: 10.1371/journal.pone.0114420.", "ArticleIdList": ["10.1371/journal.pone.0114420", "PMC4256231", "25474488"]}, {"Citation": "Yan X, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13:220.", "ArticleIdList": ["PMC4181414", "25248370"]}, {"Citation": "Zou C, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012;11(11):2137\u20132145. doi: 10.4161/cc.20598.", "ArticleIdList": ["10.4161/cc.20598", "PMC3368865", "22592534"]}, {"Citation": "Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647\u2013658. doi: 10.1016/j.cell.2009.02.038.", "ArticleIdList": ["10.1016/j.cell.2009.02.038", "19409607"]}, {"Citation": "Zheng M, Sun X, Li Y, Zuo W. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol. 2016;37(6):8189\u20138196. doi: 10.1007/s13277-015-4722-2.", "ArticleIdList": ["10.1007/s13277-015-4722-2", "26715279"]}, {"Citation": "Wang S, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 2009;34(5):1461\u20131466.", "ArticleIdList": ["19360360"]}, {"Citation": "Zhao H, et al. miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res. 2016;8(7):3106\u20133114.", "ArticleIdList": ["PMC4969447", "27508031"]}, {"Citation": "Gao M, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7(37):59714\u201359726. doi: 10.18632/oncotarget.10845.", "ArticleIdList": ["10.18632/oncotarget.10845", "PMC5312343", "27487127"]}, {"Citation": "G\u00f6tte M, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010;29(50):6569\u20136580. doi: 10.1038/onc.2010.386.", "ArticleIdList": ["10.1038/onc.2010.386", "20818426"]}, {"Citation": "Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697. doi: 10.1038/nmeth.3485.", "ArticleIdList": ["10.1038/nmeth.3485", "26226356"]}, {"Citation": "Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357.", "ArticleIdList": ["19131956"]}, {"Citation": "Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1\u201313. doi: 10.1093/nar/gkn923.", "ArticleIdList": ["10.1093/nar/gkn923", "PMC2615629", "19033363"]}, {"Citation": "Ponting CP, Benjamin DR. A novel family of Ras-binding domains. Trends Biochem Sci. 1996;21(11):422\u2013425. doi: 10.1016/S0968-0004(96)30038-8.", "ArticleIdList": ["10.1016/S0968-0004(96)30038-8", "8987396"]}, {"Citation": "Gatza ML, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15):6994\u20136999. doi: 10.1073/pnas.0912708107.", "ArticleIdList": ["10.1073/pnas.0912708107", "PMC2872436", "20335537"]}, {"Citation": "Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013;23(13):3741\u20133748. doi: 10.1016/j.bmcl.2013.05.007.", "ArticleIdList": ["10.1016/j.bmcl.2013.05.007", "23726034"]}, {"Citation": "Zhang M, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008;68(12):4674\u20134682. doi: 10.1158/0008-5472.CAN-07-6353.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-6353", "PMC2459340", "18559513"]}, {"Citation": "Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci. 2008;4(3):133\u2013142.", "ArticleIdList": ["PMC2367429", "18461147"]}, {"Citation": "Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res. 2016;18(1):9. doi: 10.1186/s13058-015-0668-y.", "ArticleIdList": ["10.1186/s13058-015-0668-y", "PMC4717616", "26781438"]}, {"Citation": "Suzuki HI, Young RA, Sharp PA. Super-enhancer-mediated RNA processing revealed by integrative microRNA network analysis. Cell. 2017;168(6):1000\u20131014.e15. doi: 10.1016/j.cell.2017.02.015.", "ArticleIdList": ["10.1016/j.cell.2017.02.015", "PMC5350633", "28283057"]}, {"Citation": "Fu NY, et al. EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nat Cell Biol. 2015;17(4):365\u2013375. doi: 10.1038/ncb3117.", "ArticleIdList": ["10.1038/ncb3117", "25730472"]}, {"Citation": "Marsh V, Davies EJ, Williams GT, Clarke AR. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. J Pathol. 2013;230(2):165\u2013173. doi: 10.1002/path.4189.", "ArticleIdList": ["10.1002/path.4189", "23483557"]}, {"Citation": "Frew IJ, et al. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol. 2008;28(14):4536\u20134548. doi: 10.1128/MCB.02132-07.", "ArticleIdList": ["10.1128/MCB.02132-07", "PMC2447121", "18474617"]}, {"Citation": "Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400\u2013407. doi: 10.1158/1078-0432.CCR-11-2283.", "ArticleIdList": ["10.1158/1078-0432.CCR-11-2283", "PMC3261579", "22252256"]}, {"Citation": "Riegert-Johnson DL, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8(1):6. doi: 10.1186/1897-4287-8-6.", "ArticleIdList": ["10.1186/1897-4287-8-6", "PMC2904729", "20565722"]}, {"Citation": "Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143\u2013153. doi: 10.1038/nrclinonc.2013.10.", "ArticleIdList": ["10.1038/nrclinonc.2013.10", "23400000"]}, {"Citation": "Serra V, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30(22):2547\u20132557. doi: 10.1038/onc.2010.626.", "ArticleIdList": ["10.1038/onc.2010.626", "PMC3107390", "21278786"]}, {"Citation": "Jokinen E, Koivunen JP. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol. 2015;7(3):170\u2013180. doi: 10.1177/1758834015571111.", "ArticleIdList": ["10.1177/1758834015571111", "PMC4406912", "26673580"]}, {"Citation": "Welsch ME, et al. Multivalent small-molecule pan-RAS inhibitors. Cell. 2017;168(5):878\u2013889.e29. doi: 10.1016/j.cell.2017.02.006.", "ArticleIdList": ["10.1016/j.cell.2017.02.006", "PMC5362268", "28235199"]}, {"Citation": "Wagner KU, et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 1997;25(21):4323\u20134330. doi: 10.1093/nar/25.21.4323.", "ArticleIdList": ["10.1093/nar/25.21.4323", "PMC147032", "9336464"]}, {"Citation": "Deng T, et al. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. Cancer Res. 2014;74(7):2119\u20132130. doi: 10.1158/0008-5472.CAN-13-2138.", "ArticleIdList": ["10.1158/0008-5472.CAN-13-2138", "24487029"]}, {"Citation": "Liu JC, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER\u03b1\u2013 breast cancer. Proc Natl Acad Sci U S A. 2012;109(15):5832\u20135837. doi: 10.1073/pnas.1201105109.", "ArticleIdList": ["10.1073/pnas.1201105109", "PMC3326451", "22460789"]}, {"Citation": "Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201315550. doi: 10.1073/pnas.0506580102.", "ArticleIdList": ["10.1073/pnas.0506580102", "PMC1239896", "16199517"]}, {"Citation": "Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984. doi: 10.1371/journal.pone.0013984.", "ArticleIdList": ["10.1371/journal.pone.0013984", "PMC2981572", "21085593"]}]}], "History": [{"Year": "2017", "Month": "2", "Day": "8"}, {"Year": "2017", "Month": "6", "Day": "23"}, {"Year": "2017", "Month": "8", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "5", "Hour": "6", "Minute": "1"}, {"Year": "2017", "Month": "8", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["28768903", "PMC5543917", "10.1172/jci.insight.93313", "93313"]}}]}